Xtl Biopharmaceuticals (XTLB) Total Liabilities (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Total Liabilities for 17 consecutive years, with $1.9 million the latest figure, recorded in Q4 2025.

• Quarterly Total Liabilities changed 0.0% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (changed 0.0% YoY) and the FY2025 annual result came in at $1.9 million, changed 0.0% from the prior year.
• Total Liabilities rose to $1.9 million in Q4 2025 per XTLB's latest filing, from $714000.0 in the prior quarter.
• Over the last five years, Total Liabilities for XTLB reached as high as $9.3 million in Q3 2024 and fell as low as $153000.0 in Q3 2022.
• A 5-year average of $2.5 million and a median of $477500.0 in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities tumbled 97.77% — and 2024, when it soared 5628.4%.
• Year by year, Total Liabilities stood at $1.3 million in 2021, then tumbled by 85.45% to $187000.0 in 2022, then increased by 10.16% to $206000.0 in 2023, then jumped by 806.31% to $1.9 million in 2024, then changed by 0.0% to $1.9 million in 2025.
• According to Business Quant data, Total Liabilities over the past three periods registered $1.9 million, $714000.0, and $1.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.